Work Here?
Tenvie Therapeutics
Work Here?
Develops precision CNS-penetrant small molecules
Tenvie Therapeutics
Work Here?
Develops precision CNS-penetrant small molecules
Overview
Tenvie Therapeutics develops small-molecule drugs aimed at neurological diseases, with a focus on molecules designed to cross the blood-brain barrier and reach the central nervous system effectively. Its leading strategy is to optimize molecular delivery properties so CNS penetration is improved, maximizing benefits for patients. The company maintains a diverse pipeline of proprietary assets, including programs acquired from Denali Therapeutics, and monetizes its work by advancing these CNS-targeted therapies in clinical development. Led by President and Chief Scientific Officer Tony Estrada, the team emphasizes CNS drug development expertise to pursue patient-focused outcomes.
About Tenvie Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Early VC
Total Funding
$200M
Headquarters
San Francisco, California
Founded
2025
Get referred to Tenvie Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- April 2026 first-subject dosing de-risked execution for both TNV262 and TNV108.
- June 2026 UBS messaging signaled first NLRP3 biomarker data in Q4 2026.
- February 2026 hiring of Don O’Sullivan strengthened partnering and business development ahead of data.
What critics are saying
- TNV262 and TNV108 remain early Phase 1 programs; failure erases the platform narrative.
- The company’s obesity and cardiovascular thesis depends on Q4 2026 biomarker readouts meeting investor expectations.
- No disclosed commercialization path exists; by 2027, Tenvie stays a financing-dependent clinical biotech.
What makes Tenvie Therapeutics unique
- 2026 launches two clinical assets: TNV262, a CNS-penetrant NLRP3 inhibitor, and TNV108 SARM1 inhibitor.
- Tenvie’s platform explicitly optimizes brain penetration and peripheral restriction for precision-designed small molecules.
- Denali-acquired neuroscience assets give Tenvie inherited chemistry, targets, and development continuity.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$200M
Above
Industry Average
Funded Over
1 Rounds
Benefits
Remote Work Options
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 0%Tenvie Therapeutics promotes Tony Estrada, phd, to Chief Executive Officer.
In Q1 2025, biopharma venture funding surged, with Verdiva Bio launching with a $411 million series A, co-led by Forbion and General Atlantic, to develop therapies for obesity and cardiometabolic diseases. Other notable funding rounds included Aviceda Therapeutics' $208 million series C, Abcuro's $200 million series C, Windward Bio's $200 million series A, and Tenvie Therapeutics' $200 million seed funding.
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates.
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team...
Tenvie Therapeutics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Tenvie Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Early VC
Total Funding
$200M
Headquarters
San Francisco, California
Founded
2025
Tenvie Therapeutics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today